An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)

Investigating the Effectiveness of Renal Anaemia Treatment in Pre-Dialysis Patients With Mircera in Daily Clinical Practice - MIRVITA

This observational trial will examine the efficacy and safety of Mircera for renal anemia in participants with stage III-IV CKD in daily clinical practice. Mircera will be prescribed by treating physician and followed for approximately 36 months.

Inclusion Criteria:

• Participants aged > 18 years with CKD
• Participants who are eligible for Mircera treatment according to current guidelines and summary of product characteristics (SmPC)

Exclusion Criteria:

• Non-renal anemia
• Pregnancy and breast-feeding
• Uncontrolled hypertension
• Known hypersensitivity to methoxy polyethylene glycol-epoetin beta
• Administration of any other study drug within 30 days prior to study enrollment